Vertex Pharmaceuticals price to free cash flow VRTX

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 35.0×
10-year median: 32.5×
Against its 10-year history: 60th; percentile: 0 is its lowest day, 100 its highest
10-year range: 16.0× to 164×
Peer median: 19.9×

Vertex Pharmaceuticals' price to free cash flow is 35.0× as of Oct 23, 2026.

That is above its ten-year median of 32.5×, close to the middle of its last ten years.

Over that time it ranged from 16.0× in Jun 2021 to 164× in Apr 2017.

The median for 8 biotech stocks of a similar size is 19.9×.

Price to free cash flow over time

median 32.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.0×	29.4×	39.5×
2025	35.2×	26.9×	35.2×
2024	34.3×	25.5×	34.4×
2023	24.9×	18.8×	25.2×
2022	19.4×	19.0×	32.2×
2021	29.1×	16.0×	29.6×
2020	20.6×	18.8×	46.9×
2019	41.7×	30.3×	46.9×
2018	38.9×	37.7×	64.4×
2017	54.9×	51.6×	164×
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	150×	14.5×	167×
2012	13.1×	12.4×	82.8×

Against its peers

Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
VRTXVertex Pharmaceuticals	35.0×
REGNRegeneron Pharmaceuticals	22.0×
ONCBeOne Medicines	32.3×
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	23.1×
INCYIncyte	12.2×
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
Peer median	19.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Vertex Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.